ADVERTISEMENT
Biotech giant is slipping after revealing its 2017 guidance
Shares of biotech company Gilead were down as much as 4% after-hours Tuesday after revealing a disappointing guidance for 2017.
Screen Shot 2017 02 07 at 4.14.39 PM
ADVERTISEMENT
The company, known for its HIV and hepatitis C drugs, posted lower fourth-quarter profits as fewer patients were treated with its pricey hepatitis C drugs. The company also said total product sales would be lower this year.
Gilead's earnings per share came in at $2.34, compared to analysts' estimates of
Fourth-quarter net income fell to $3.1 billion from $4.7 billion a year earlier. Adjusting for one-time items,said it earned $2.70 per share in the quarter, compared with $3.32 per share a year earlier.
ADVERTISEMENT
Quarterly sales of hepatitis C drugs Sovaldi, Harvoni, and Epclusa totaled $3.2 billion, compared with $4.9 billion a year earlier. Wall Street analysts, on average, had forecast hepatitis C drug sales of $3.2 billion, according to a poll by Evercore ISI.
FOLLOW BUSINESS INSIDER AFRICA
ADVERTISEMENT
Recommended articles
A look into the diverse tax reforms being implemented across Africa
Dubai firm to lend South Sudan $12.9 billion in exchange for 20 years oil repayment
China dethrones USA as the most influential global power in Africa: Report
Major African economies expecting inflation ease into next year, except Nigeria
10 African countries with the lowest price changes in household commodities
Dangote refinery outranks Europe's 10 largest refining facilities
Africa may just have the lowest level of cyber threats compared to other regions
A look into Kenya’s Shs1.1 billion climate funding from the UK